UY27403A1 - 2-(3,5-bis-trifluormetil-fenil)-n-(6-(1,1-dioxo-16-tiomorfolin-4-il)-4-(2-metil ó 4-fluor-2- metil substituidos)fenil-piridin-3-il)-n-metil-isobutiramida. - Google Patents
2-(3,5-bis-trifluormetil-fenil)-n-(6-(1,1-dioxo-16-tiomorfolin-4-il)-4-(2-metil ó 4-fluor-2- metil substituidos)fenil-piridin-3-il)-n-metil-isobutiramida.Info
- Publication number
- UY27403A1 UY27403A1 UY27403A UY27403A UY27403A1 UY 27403 A1 UY27403 A1 UY 27403A1 UY 27403 A UY27403 A UY 27403A UY 27403 A UY27403 A UY 27403A UY 27403 A1 UY27403 A1 UY 27403A1
- Authority
- UY
- Uruguay
- Prior art keywords
- methyl
- phenyl
- dioxo
- bis
- isobutyramide
- Prior art date
Links
- -1 3,5-BIS-TRIFLUORMETHYL-PHENYL Chemical class 0.000 title abstract 3
- 206010047700 Vomiting Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000008673 vomiting Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000020564 Eye injury Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 206010048010 Withdrawal syndrome Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La invención se refiere a los siguientes compuestos 2-(3,5-bis-trifluorometil-fenil)-N-(6-(1,1-dioxo-1,6-tiomorfolin-4-il)-4-o-tolil-piridin-3-il)-N-metil-isobutiramida y 2-(3,5-bis-trifluorometil-fenil)-N(6-(1,1-dioxo-1,6-tiomorfolin-4-il)-4-(4-fluoro-2-metil-fenil)-piridin-3-il)-N-metil-isobutiramida, que pueden utilizarse en el tratamiento de la migrana, artritis reumatoide, asma, hiper reactividad de bronquios, enfermedades intestinales inflamatorias o en el tratamiento de desórdenes tales como la enfermedad de Alzheimer, esclerosis múltiple edema, rinitis alérgica, enfermedad de Crohn, lesiones oculares, enfermedades inflamatorias oculares, psicosis, náuseas, vómitos inducidos, vómitos, incontinencia urinaria, desórdenes psicosomáticos o psicoinmunológicos, cáncer, síndrome de abstinencia a drogas de adicción de opiatos o nicotina, lesiones cerebrales traumáticas o hiperplasia protática benigna.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01118412 | 2001-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27403A1 true UY27403A1 (es) | 2003-04-30 |
Family
ID=8178193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27403A UY27403A1 (es) | 2001-07-31 | 2002-07-30 | 2-(3,5-bis-trifluormetil-fenil)-n-(6-(1,1-dioxo-16-tiomorfolin-4-il)-4-(2-metil ó 4-fluor-2- metil substituidos)fenil-piridin-3-il)-n-metil-isobutiramida. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6849624B2 (es) |
| EP (1) | EP1414525B1 (es) |
| JP (1) | JP4700908B2 (es) |
| KR (1) | KR100577101B1 (es) |
| CN (1) | CN1289497C (es) |
| AR (1) | AR034921A1 (es) |
| AT (1) | ATE430600T1 (es) |
| BR (1) | BR0211523A (es) |
| CA (1) | CA2452502C (es) |
| DE (1) | DE60232246D1 (es) |
| EA (1) | EA006238B1 (es) |
| EC (1) | ECSP044963A (es) |
| ES (1) | ES2324209T3 (es) |
| GT (1) | GT200200159A (es) |
| HK (1) | HK1069136A1 (es) |
| HR (1) | HRP20040039A2 (es) |
| HU (1) | HUP0400398A3 (es) |
| MA (1) | MA27055A1 (es) |
| MX (1) | MXPA04000917A (es) |
| MY (1) | MY128464A (es) |
| NO (1) | NO20040404L (es) |
| NZ (1) | NZ530579A (es) |
| PA (1) | PA8551601A1 (es) |
| PE (1) | PE20030276A1 (es) |
| PL (1) | PL366986A1 (es) |
| UA (1) | UA77685C2 (es) |
| UY (1) | UY27403A1 (es) |
| WO (1) | WO2003011860A2 (es) |
| YU (1) | YU2704A (es) |
| ZA (1) | ZA200400652B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2444395C (en) * | 2001-04-23 | 2010-12-21 | F. Hoffmann-La Roche Ag | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
| SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| JP4708795B2 (ja) | 2002-12-20 | 2011-06-22 | ニコノヴァム エービー | 物理的および化学的に安定なニコチン−含有粒状物質 |
| NZ541243A (en) * | 2003-01-31 | 2008-04-30 | Hoffmann La Roche | New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide |
| DE602005026669D1 (de) | 2004-07-06 | 2011-04-14 | Hoffmann La Roche | Herstellungsverfahren für carboxamid-pyridin-derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten |
| KR100902425B1 (ko) * | 2005-02-22 | 2009-06-11 | 에프. 호프만-라 로슈 아게 | Ｎｋ１ 길항제 |
| KR20070094666A (ko) | 2005-02-25 | 2007-09-20 | 에프. 호프만-라 로슈 아게 | 약제 물질 분산성이 향상된 정제 |
| CA2646942C (en) | 2006-03-16 | 2014-07-29 | Niconovum Ab | Improved snuff composition |
| GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| US10383894B2 (en) * | 2010-03-17 | 2019-08-20 | Lutran Industries, Inc. | Human medicinal treatment using salt of peroxymonosulfuric acid |
| KR20160078997A (ko) | 2013-11-08 | 2016-07-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 카복시메틸피페리딘 유도체 |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| AU2016226006B2 (en) | 2015-03-04 | 2021-03-04 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| CN112218636A (zh) * | 2018-06-08 | 2021-01-12 | 万达制药公司 | 使用川地匹坦进行治疗的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6435115A (en) * | 1987-07-31 | 1989-02-06 | Nippon Seiko Kk | Bearing device |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| DE69434991T2 (de) | 1993-12-29 | 2008-03-06 | Merck Sharp & Dohme Ltd., Hoddesdon | Substituierte Morpholinderivate und ihre Verwendung als Arzneimittel |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| CA2444395C (en) | 2001-04-23 | 2010-12-21 | F. Hoffmann-La Roche Ag | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
-
2002
- 2002-07-17 US US10/196,795 patent/US6849624B2/en not_active Expired - Fee Related
- 2002-07-25 PE PE2002000667A patent/PE20030276A1/es not_active Application Discontinuation
- 2002-07-26 KR KR1020047001322A patent/KR100577101B1/ko not_active IP Right Cessation
- 2002-07-26 DE DE60232246T patent/DE60232246D1/de not_active Expired - Lifetime
- 2002-07-26 HU HU0400398A patent/HUP0400398A3/hu unknown
- 2002-07-26 MX MXPA04000917A patent/MXPA04000917A/es active IP Right Grant
- 2002-07-26 WO PCT/EP2002/008311 patent/WO2003011860A2/en active IP Right Grant
- 2002-07-26 PA PA20028551601A patent/PA8551601A1/es unknown
- 2002-07-26 YU YU2704A patent/YU2704A/sh unknown
- 2002-07-26 AT AT02791471T patent/ATE430600T1/de active
- 2002-07-26 BR BR0211523-9A patent/BR0211523A/pt not_active Application Discontinuation
- 2002-07-26 PL PL02366986A patent/PL366986A1/xx not_active Application Discontinuation
- 2002-07-26 JP JP2003517052A patent/JP4700908B2/ja not_active Expired - Fee Related
- 2002-07-26 CN CNB028151100A patent/CN1289497C/zh not_active Expired - Fee Related
- 2002-07-26 EA EA200400109A patent/EA006238B1/ru not_active IP Right Cessation
- 2002-07-26 NZ NZ530579A patent/NZ530579A/en unknown
- 2002-07-26 CA CA2452502A patent/CA2452502C/en not_active Expired - Fee Related
- 2002-07-26 EP EP02791471A patent/EP1414525B1/en not_active Expired - Lifetime
- 2002-07-26 ES ES02791471T patent/ES2324209T3/es not_active Expired - Lifetime
- 2002-07-26 UA UA2004021462A patent/UA77685C2/uk unknown
- 2002-07-29 AR ARP020102847A patent/AR034921A1/es not_active Application Discontinuation
- 2002-07-29 MY MYPI20022848A patent/MY128464A/en unknown
- 2002-07-30 UY UY27403A patent/UY27403A1/es not_active Application Discontinuation
- 2002-07-31 GT GT200200159A patent/GT200200159A/es unknown
-
2004
- 2004-01-15 HR HR20040039A patent/HRP20040039A2/hr not_active Application Discontinuation
- 2004-01-27 ZA ZA200400652A patent/ZA200400652B/xx unknown
- 2004-01-29 NO NO20040404A patent/NO20040404L/no unknown
- 2004-01-29 EC EC2004004963A patent/ECSP044963A/es unknown
- 2004-01-30 MA MA27507A patent/MA27055A1/fr unknown
-
2005
- 2005-02-28 HK HK05101662A patent/HK1069136A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27403A1 (es) | 2-(3,5-bis-trifluormetil-fenil)-n-(6-(1,1-dioxo-16-tiomorfolin-4-il)-4-(2-metil ó 4-fluor-2- metil substituidos)fenil-piridin-3-il)-n-metil-isobutiramida. | |
| WO2007038209A3 (en) | Fused tetracyclic mglur1 antagonists as therapeutic agents | |
| MXPA04000793A (es) | Novedoso metodo terapeutico. | |
| BRPI0509391A (pt) | piridonas substituìdos como inibidores de poli(adp-ribose) polimerase (parp) | |
| TW200609231A (en) | Mglur1 antagonists as therapeutic agents | |
| BR9408174A (pt) | Compostos isoxazolina como agentes antiinflamatórios | |
| MX2007004781A (es) | Derivados de 3-arilamino piridina. | |
| ES2139754T3 (es) | 3-fenil-2-isoxazolinas como agentes antiinflamatorios. | |
| DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
| PA8527301A1 (es) | 7-oxo-piridopirimidinas | |
| NO20072558L (no) | Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav | |
| GB0223040D0 (en) | Therapeutic compounds | |
| TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
| NO20080125L (no) | 2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament | |
| WO2006057945A3 (en) | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
| DK1593387T3 (da) | Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser | |
| TW200735868A (en) | Compositions and methods for treating CNS disorders | |
| MX2008002366A (es) | Antagonistas triciclicos fusionados de mglur1 como agentes terapeuticos. | |
| PL372179A1 (en) | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | |
| DK1648880T3 (da) | Terapeutiske midler, der kan anvendes til behandling af smerte | |
| MY127426A (en) | 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide | |
| TW200740826A (en) | Fused tricyclic mGluR1 antagonists as therapeutic agents | |
| JP2005500354A5 (es) | ||
| BR0008382A (pt) | Formulação de liberação controlada para tratamento de copd | |
| GB0612026D0 (en) | New use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20141218 |